Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 461,661 shares, an increase of 609.4% from the August 15th total of 65,075 shares. Based on an average daily volume of 5,622,745 shares, the short-interest ratio is currently 0.1 days. Approximately 65.3% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on AEMD shares. HC Wainwright reaffirmed a “neutral” rating and set a $1.50 target price on shares of Aethlon Medical in a research report on Tuesday, August 18th. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a report on Friday, July 17th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $1.50.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC acquired a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission. 1.99% of the stock is currently owned by hedge funds and other institutional investors.

Aethlon Medical Trading Down 7.7%

NASDAQ:AEMD opened at $1.56 on Friday. The stock has a market capitalization of $1.11 million, a PE ratio of -0.04 and a beta of 1.40. The firm’s 50 day moving average is $2.83 and its 200 day moving average is $7.53. Aethlon Medical has a 12 month low of $1.55 and a 12 month high of $41.35.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share for the quarter, missing the consensus estimate of ($3.92) by ($0.10). Research analysts predict that Aethlon Medical will post -5.74 earnings per share for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.